FIELD: immunology; medicine.
SUBSTANCE: invention relates to immunology and medicine, in particular to an isolated monovalent antibody or its fragment, which specifically bind to human properdin, a bispecific antibody or its fragment, which specifically bind to human properdin and human serum albumin. Compositions for inhibition of an alternative path of a complement, containing such antibodies or their fragments, are also disclosed.
EFFECT: present invention allows for expansion of the arsenal of means for inhibition of properdin activity, which is an important therapeutic strategy for suppression of symptoms and delayed progression of diseases associated with a disorder of regulation of an alternative path of a complement.
10 cl, 20 dwg, 9 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
PARVOVIRUS ANTIBODIES FOR USE IN VETERINARY SCIENCE | 2020 |
|
RU2830441C2 |
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
BISPECIFIC ANTIBODIES | 2020 |
|
RU2818588C2 |
ANTIBODIES TO MESOTHELIN | 2019 |
|
RU2837574C2 |
ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
BISPECIFIC ANTIBODY | 2021 |
|
RU2840407C1 |
Authors
Dates
2023-02-14—Published
2018-01-30—Filed